Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3422]
News [7838]
Articles [63]
Editorials [9]
Conferences [211]
elearning [49]
WCLC 2024: Dexamethasone reduces infusion-related reactions in patients with EGFR-mutated non-small cell lung cancer treated with intravenous amivantamab-vmjw
WCLC 2024: Dexamethasone reduces infusion-related reactions in patients with EGFR-mutated non-small cell lung...
ESMO 2024: Encoradenib & binimetinib shows long-term clinically meaningful response in patients with BRAF V600E-mutant metastatic non-small Cell lung cancer
ESMO 2024: Encoradenib & binimetinib shows long-term clinically meaningful response in patients with BRAF V600E...
ESMO 2024: Neoadjuvant TAR-200 plus cetrelimab nearly doubles the pathological complete response rate compared to cetrelimab alone in patients with muscle-invasive bladder cancer
ESMO 2024: Neoadjuvant TAR-200 plus cetrelimab nearly doubles the pathological complete response rate compared to...
Novel triplet regimen yields promising response in advanced-phase chronic myeloid leukaemia
Novel triplet regimen yields promising response in advanced-phase chronic myeloid leukaemia
New research shows how oral cancer cells avoid immune system
New research shows how oral cancer cells avoid immune system
ESMO 2024: Alternating pazopanib bevacizumab regimen doubles progression-free survival in metastatic kidney cancer
ESMO 2024: Alternating pazopanib bevacizumab regimen doubles progression-free survival in metastatic kidney cancer
New drug target discovered for aggressive form of prostate cancer
New drug target discovered for aggressive form of prostate cancer
Breakthrough study reveals how mutant p53 protein converts other proteins into cancer drivers
Breakthrough study reveals how mutant p53 protein converts other proteins into cancer drivers
ESMO 2024: Immunotherapy improves long-term survival in growing number of cancers
ESMO 2024: Immunotherapy improves long-term survival in growing number of cancers
Tumor-induced B cell changes reveal potential biomarker for treatment response in triple negative breast cancer
Tumor-induced B cell changes reveal potential biomarker for treatment response in triple negative breast cancer

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation